For this study, researchers from Great Basin Corporation in Salt Lake City, Denver Health Hospital and the Children’s Memorial Hospital in Chicago assessed the sensitivity and specificity of the Staph ID/R test and determined Staph ID/R has excellent specificity with no non-specific cross-reactivity observed.
“A significant advantage of the Staph ID/R test is that it can provide species information that may significantly speed up the diagnosis process, ensuring patients get the right treatment sooner,” said the lead author of the study. “Also, nearly one-third of all positive blood cultures are from contamination and this test can identify these cases to remove patients from costly and unnecessary therapeutic interventions.”
Great Basin Corporation intends to begin clinical trials for the Staph ID/R assay this year.
Related Articles on MRSA:
Are Contact Precautions Necessary to Decrease Risk of Infection?
Enzymatic Soap Solution Not Enough to Disinfect MRSA-Contaminated Laryngoscopes
Study Reveals High Incidence of MRSA in Children Undergoing Open Airway Surgery
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
